Corcept Therapeutics Inc CORT shares are under heavy pressure Thursday morning after the U.S. Court of Appeals for the ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds ...

In the Phase IIb trial, the drug was still benefiting patients after 58 weeks of treatment.

Corcept Therapeutics lost its patent-infringement battle with Teva Pharmaceutical Industries, exposing Corcept to more competition from generic drugs. The ruling from the U.S. Court of Appeals for the ...

Shares of Corcept Therapeutics (CORT) lost more than 20% on Thursday after a federal appeals court ruled against the company in a patent dispute with Israeli drugmaker Teva Pharmaceuticals (TEVA) ...

The latest update to Teva Pharmaceutical Industries' narrative centers on a modestly higher fair value estimate, now at US$37.95 per share compared with the prior US$36.77, reflecting how recent ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had ...

Teva Pharmaceutical Indus (NYSE: TEVA) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of ...

Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

As the biopharma industry moves into the new year, Teva is looking to put the past behind it. After proposing a blockbuster $4.25 billion opioid settlement, the drugmaker has secured participation ...

Teva Pharmaceutical Industries operates in the pharmaceuticals sector, where product mix, regulatory milestones, and ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio.